Cite
HARVARD Citation
Kedor, C. et al. (2020). Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Annals of the rheumatic diseases. 79 (8), pp. 1090-1097. [Online].